Combination Low-Dose Tissue-Type Plasminogen Activator Plus Annexin A2 for Improving Thrombolytic Stroke Therapy

Risk of hemorrhagic transformation, incomplete reperfusion, neurotoxicity, and a short treatment time window comprises major challenges for tissue plasminogen activator (tPA) thrombolytic stroke therapy. Improving tPA therapy has become one of the highest priorities in the stroke field. This mini re...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Yinghua, Fan, Xiang, Yu, Zhanyang, Liao, Zhengbu, Wang, Xiao-Shu, van Leyen, Klaus, Sun, Xiaochuan, Lo, Eng H., Wang, Xiaoying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2015
Materias:
Neuroscience
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604305/
https://www.ncbi.nlm.nih.gov/pubmed/26528130
http://dx.doi.org/10.3389/fncel.2015.00397
_version_ 1782395039126650880
author Jiang, Yinghua
Fan, Xiang
Yu, Zhanyang
Liao, Zhengbu
Wang, Xiao-Shu
van Leyen, Klaus
Sun, Xiaochuan
Lo, Eng H.
Wang, Xiaoying
author_facet Jiang, Yinghua
Fan, Xiang
Yu, Zhanyang
Liao, Zhengbu
Wang, Xiao-Shu
van Leyen, Klaus
Sun, Xiaochuan
Lo, Eng H.
Wang, Xiaoying
author_sort Jiang, Yinghua
collection PubMed
description Risk of hemorrhagic transformation, incomplete reperfusion, neurotoxicity, and a short treatment time window comprises major challenges for tissue plasminogen activator (tPA) thrombolytic stroke therapy. Improving tPA therapy has become one of the highest priorities in the stroke field. This mini review article focuses on our recent efforts aimed at evaluating a novel combination approach of low-dose tPA plus recombinant annexin A2 (rA2, a tPA, and plasminogen co-receptor), which might enhance tPA thrombolytic efficacy, while reducing its associated complications related to intracerebral hemorrhagic transformation. Results of our experimental studies using a focal embolic stroke model in rats support the feasibility of the combination approach and suggest the potential for successful clinical translation.
format Online
Article
Text
id pubmed-4604305
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-46043052015-11-02 Combination Low-Dose Tissue-Type Plasminogen Activator Plus Annexin A2 for Improving Thrombolytic Stroke Therapy Jiang, Yinghua Fan, Xiang Yu, Zhanyang Liao, Zhengbu Wang, Xiao-Shu van Leyen, Klaus Sun, Xiaochuan Lo, Eng H. Wang, Xiaoying Front Cell Neurosci Neuroscience Risk of hemorrhagic transformation, incomplete reperfusion, neurotoxicity, and a short treatment time window comprises major challenges for tissue plasminogen activator (tPA) thrombolytic stroke therapy. Improving tPA therapy has become one of the highest priorities in the stroke field. This mini review article focuses on our recent efforts aimed at evaluating a novel combination approach of low-dose tPA plus recombinant annexin A2 (rA2, a tPA, and plasminogen co-receptor), which might enhance tPA thrombolytic efficacy, while reducing its associated complications related to intracerebral hemorrhagic transformation. Results of our experimental studies using a focal embolic stroke model in rats support the feasibility of the combination approach and suggest the potential for successful clinical translation. Frontiers Media S.A. 2015-10-14 /pmc/articles/PMC4604305/ /pubmed/26528130 http://dx.doi.org/10.3389/fncel.2015.00397 Text en Copyright © 2015 Jiang, Fan, Yu, Liao, Wang, van Leyen, Sun, Lo and Wang. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Jiang, Yinghua
Fan, Xiang
Yu, Zhanyang
Liao, Zhengbu
Wang, Xiao-Shu
van Leyen, Klaus
Sun, Xiaochuan
Lo, Eng H.
Wang, Xiaoying
Combination Low-Dose Tissue-Type Plasminogen Activator Plus Annexin A2 for Improving Thrombolytic Stroke Therapy
title Combination Low-Dose Tissue-Type Plasminogen Activator Plus Annexin A2 for Improving Thrombolytic Stroke Therapy
title_full Combination Low-Dose Tissue-Type Plasminogen Activator Plus Annexin A2 for Improving Thrombolytic Stroke Therapy
title_fullStr Combination Low-Dose Tissue-Type Plasminogen Activator Plus Annexin A2 for Improving Thrombolytic Stroke Therapy
title_full_unstemmed Combination Low-Dose Tissue-Type Plasminogen Activator Plus Annexin A2 for Improving Thrombolytic Stroke Therapy
title_short Combination Low-Dose Tissue-Type Plasminogen Activator Plus Annexin A2 for Improving Thrombolytic Stroke Therapy
title_sort combination low-dose tissue-type plasminogen activator plus annexin a2 for improving thrombolytic stroke therapy
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604305/
https://www.ncbi.nlm.nih.gov/pubmed/26528130
http://dx.doi.org/10.3389/fncel.2015.00397
work_keys_str_mv AT jiangyinghua combinationlowdosetissuetypeplasminogenactivatorplusannexina2forimprovingthrombolyticstroketherapy
AT fanxiang combinationlowdosetissuetypeplasminogenactivatorplusannexina2forimprovingthrombolyticstroketherapy
AT yuzhanyang combinationlowdosetissuetypeplasminogenactivatorplusannexina2forimprovingthrombolyticstroketherapy
AT liaozhengbu combinationlowdosetissuetypeplasminogenactivatorplusannexina2forimprovingthrombolyticstroketherapy
AT wangxiaoshu combinationlowdosetissuetypeplasminogenactivatorplusannexina2forimprovingthrombolyticstroketherapy
AT vanleyenklaus combinationlowdosetissuetypeplasminogenactivatorplusannexina2forimprovingthrombolyticstroketherapy
AT sunxiaochuan combinationlowdosetissuetypeplasminogenactivatorplusannexina2forimprovingthrombolyticstroketherapy
AT loengh combinationlowdosetissuetypeplasminogenactivatorplusannexina2forimprovingthrombolyticstroketherapy
AT wangxiaoying combinationlowdosetissuetypeplasminogenactivatorplusannexina2forimprovingthrombolyticstroketherapy

Ejemplares similares